Résumé
<p><b>OBJECTIVE</b>To determine whether the increased level of serum prostate-specific antigen (PSA) could be used as a diagnostic marker of hyperandrogenism in women.</p><p><b>METHODS</b>Forty-five female patients with hyperandrogenism and 50 healthy control women were detected for the levels of serum PSA, testosterone (T), sex hormone binding globulin (SHBG) and dehydroepiandrosterone sulfate (DHEA-S). The results were statistically analyzed.</p><p><b>RESULTS</b>The level of serum PSA was found to be significantly higher in the hyperandrogenism patients than in the healthy controls (9.72 +/- 1.39 pg/ml vs 3.56 +/- 0.44 pg/ml, P < 0.01), and it showed a weak positive correlation with T (r = 0.226, P < 0.05) and DHEA-S (r = 0.255, P < 0.05), and a weak negative correlation with SHBG (r = -0,228, P < 0.05).</p><p><b>CONCLUSION</b>The increased level of PSA could be used as a diagnostic marker of hyperandrogenism in females.</p>
Sujets)
Adulte , Femelle , Humains , Jeune adulte , Indice de masse corporelle , Études cas-témoins , Hyperandrogénie , Sang , Diagnostic , Antigène spécifique de la prostate , Sang , Globuline de liaison aux hormones sexuellesRésumé
<p><b>OBJECTIVE</b>To develop a method of radioimmunoassay for human sperm protein 17(Sp17) determination.</p><p><b>METHODS</b>Anti-recombinant human Sp17 antibody was prepared, the labeling of 125I-rhSp17 performed by chloramine T method, and radioimmunoassay of Sp17 developed.</p><p><b>RESULTS</b>The assay range was 3.3 to approximately 800 microg/L, the sensitivity was 2.0 microg/L, and the intra- and inter-assay coefficients of variation (CV) were 7.5% to approximately 9.8% and 8.2% to approximately 13.2%, respectively. The serum Sp17 level in normal subjects was (15.60 +/- 7.66) microg/L (n = 59).</p><p><b>CONCLUSION</b>This radioimmunoassay of Sp17 fulfills the reasonable requirements of clinical routine and scientific studies in terms of specificity, sensitivity and practicability. Measurement of Sp17 concentration is useful for assessing its native distribution and aberrant expression.</p>
Sujets)
Animaux , Femelle , Humains , Lapins , Antigènes de surface , Sang , Allergie et immunologie , Protéines de transport , Sang , Allergie et immunologie , Dosage radioimmunologique , Méthodes , Protéines recombinantes , Allergie et immunologie , Reproductibilité des résultats , Sensibilité et spécificitéRésumé
<p><b>OBJECTIVE</b>To investigate plasma endothelin-1 (ET-1) level in patients with prostate cancers and its clinical significance.</p><p><b>METHODS</b>Plasma ET-1 level was measured by radioimmunoassay in 31 patients of prostate cancer (23 with non-HRPC, 8 with HRPC) and 26 patients of BPH.</p><p><b>RESULTS</b>Compared with each other of the ET-1 level, there were no significant difference among the BPH group,non-HRPC group and HRPC group. No significant difference was found either between bone metastasis (BM) and non- BM, between high and middling differentiation prostate cancer group, as well as in different PSA level groups (P >0.05). But the ET-1 level in low differentiation prostate cancer was notably lower than those of the high and middle respectively (P < 0.05).</p><p><b>CONCLUSION</b>To detect plasma endothelin-1 (ET-1) level is not a useful method to evaluate the development and the prognosis of prostate cancer.</p>